Geneva - 29 January 2019 - Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases initiative (DNDi) have launched the Pandemic Response Box to provide researchers with free access to ...
Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2 ...
Africa: MMV Welcomes African Leaders' Call to Address Growing Threat of Antimalarial Drug Resistance
The unified stance from the World Health Organization's African Member States signals strengthened regional resolve and global collaboration to tackle emerging drug resistance African Member States, ...
Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for a long-acting injectable (LAI) preventive compound for malaria. The trial, conducted in healthy ...
Novartis and Medicines for Malaria Venture have reported positive results from the Phase IIb study, evaluating a new non-artemisinin combination to treat uncomplicated malaria in children. Novartis ...
New financing option lowers entry barriers for Circus enterprise customers and accelerates commercial rollout in 2026. For MMV, the collaboration represents a strategic step to gain early access to ...
After more than a year of pre-publicity, a major scheme to bring private and public sectors together in the search for new drugs against malaria was launched officially in Geneva last month. But even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results